Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9. https://doi.org/10.1038/nature10673.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. https://doi.org/10.1126/science.aar4060.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 22;12(4):252–64. https://doi.org/10.1038/nrc3239.

Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517–9. https://doi.org/10.1056/NEJMe1205943.

Article  CAS  PubMed  Google Scholar 

• Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori. 2017;103(5):405–21. https://doi.org/10.5301/tj.5000625. Comprehensive narrative review on the pathogenesis, clinical entities, and management of immune-related adverse events.

Article  CAS  PubMed  Google Scholar 

•• Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55. https://doi.org/10.1056/NEJMoa1609214. The first report of fulminant immune-related myocarditis in patients treated with immune checkpoint inhibitors.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https://doi.org/10.1016/S0140-6736(18)30533-6.

Article  PubMed  PubMed Central  Google Scholar 

•• Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58. https://doi.org/10.1016/S1470-2045(18)30457-1. Comprehensive narrative review on cardiovascular adverse events related to immune checkpoint inhibitors.

Article  CAS  PubMed  Google Scholar 

•• Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. https://doi.org/10.1016/j.jacc.2018.02.037. Data from a multi-institutional registry on the presentation and clinical course of 35 cases of immune-related myocarditis.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89. https://doi.org/10.1016/S1470-2045(18)30608-9. A retrospective study based on data from the pharmacovigilance registry of World Health Organization assessing myocarditis, pericardial disease, and vasculitis associated with immune checkpoint inhibitors.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018;4(12):1721-1728. https://doi.org/10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol 2018;4(12):1792. Meta-analysis of fatal toxicities related to immune checkpoint inhibitors.

Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000261. https://doi.org/10.1136/jitc-2019-000261.

Article  PubMed  PubMed Central  Google Scholar 

Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879–86. https://doi.org/10.1634/theoncologist.2018-0130.

Article  PubMed  PubMed Central  Google Scholar 

Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, et al. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front Cardiovasc Med. 2022;9:930797. https://doi.org/10.3389/fcvm.2022.930797.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res. 2007;101(3):248–57. https://doi.org/10.1161/CIRCRESAHA.106.147124.

Article  CAS  PubMed  Google Scholar 

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–22. https://doi.org/10.1126/science.291.5502.319.

Article  CAS  PubMed  Google Scholar 

Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477–83. https://doi.org/10.1038/nm955.

Article  CAS  PubMed  Google Scholar 

•• Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019; 115(5):854-868. https://doi.org/10.1093/cvr/cvz026. Erratum in: Cardiovasc Res 2019;115(5):868. Comprehensive narrative review on myocarditis, pericardial disease, and vasculitis associated with immune checkpoint inhibitors.

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017;5(1):91. https://doi.org/10.1186/s40425-017-0296-4.

Article  PubMed  PubMed Central  Google Scholar 

National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v. 5.0

Naqash AR, Moey MYY, Cherie Tan XW, Laharwal M, Hill V, Moka N, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the national cancer institute-cancer therapy evaluation program. J Clin Oncol. 2022;40(29):3439–52. https://doi.org/10.1200/JCO.22.00369.

Article  CAS  PubMed  Google Scholar 

Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021;26(12):1052–61. https://doi.org/10.1002/onco.13931.

Article  PubMed  PubMed Central  Google Scholar 

•• Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, et al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol. 2018;34(8):1059–68. https://doi.org/10.1016/j.cjca.2018.03.012. A systematic review on cardiovascular toxicity of immune checkpoint inhibitors.

Article  PubMed  Google Scholar 

• Furukawa A, Tamura Y, Taniguchi H, Kawamura A, Nagase S, Hayashi A, et al. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. J Cardiol. 2022;S0914–5087(22):00179–84. https://doi.org/10.1016/j.jjcc.2022.07.009. Prospective study on the role of monitoring troponin in patients treated with immune checkpoint inhibitors.

Article  Google Scholar 

• Spallarossa P, Tini G, Sarocchi M, Arboscello E, Grossi F, Queirolo P, et al. Identification and management of immune checkpoint inhibitor-related myocarditis: use troponin Wisely. J Clin Oncol. 2019;37(25):2201–5. https://doi.org/10.1200/JCO.18.02464. A critical view on the role of monitoring troponin for early detection of immune-related myocarditis.

Article  CAS  PubMed  Google Scholar 

Sarocchi M, Grossi F, Arboscello E, et al. Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist. 2018;23(8):936–42. https://doi.org/10.1634/theoncologist.2017-0452.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39(36):4073-4126. https://doi.org/10.1200/JCO.21.01440. Erratum in: J Clin Oncol 2022 Jan 20;40(3):315. Updated ASCO guidelines on the management of immune-related adverse events.

Awadalla M, Mahmood SS, Groarke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75(5):467–78. https://doi.org/10.1016/j.jacc.2019.11.049.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cau R, Solinas C, De Silva P, Lambertini M, Agostinetto E, Scartozzi M, et al. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis. Int J Cancer. 2022;151(11):1860–73. https://doi.org/10.1002/ijc.34169.

Article  CAS  PubMed  Google Scholar 

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87. https://doi.org/10.1016/j.jacc.2009.02.007.

Article  PubMed  PubMed Central  Google Scholar 

Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis. J Am Coll Cardiol. 2021;77(12):1503–16. https://doi.org/10.1016/j.jacc.2021.01.050.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733–43. https://doi.org/10.1093/eurheartj/ehaa051.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faron A, Isaak A, Mesropyan N, Reinert M, Schwab K, Sirokay J, et al. Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study. Radiology. 2021;301(3):602–9. https://doi.org/10.1148/radiol.2021210814.

Article  PubMed  Google Scholar 

Ederhy S, Devos P, Pinna B, Funck-Brentano E, Abbar B, Fenioux C, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. Arch Cardiovasc Dis. 2022;115(2):114–6. https://doi.org/10.1016/j.acvd.2021.12.001.

Article  PubMed  Google Scholar 

Porcari A, Baggio C, Fabris E, Merlo M, Bussani R, Perkan A, et al. Endomyocardial biopsy in the clinical context: current indications and challenging scenarios. Heart Fail Rev 2022;1–13. https://doi.org/10.1007/s10741-022-10247-5.

• Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141(24):2031–4. https://doi.org/10.1161/CIRCULATIONAHA.119.044703. Retrospective observational study based on an international registry of immune-related myocarditis.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244. Updated guidelines on cardio-oncology of the European Society of Cardiology.

Article  PubMed